ANGLE plc

AIM:AGL Stock Report

Market Cap: UK£32.3m

ANGLE Valuation

Is AGL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGL?

Key metric: As AGL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AGL. This is calculated by dividing AGL's market cap by their current revenue.
What is AGL's PS Ratio?
PS Ratio15.9x
SalesUK£2.02m
Market CapUK£32.25m

Price to Sales Ratio vs Peers

How does AGL's PS Ratio compare to its peers?

The above table shows the PS ratio for AGL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11x
BELL Belluscura
12x151.8%UK£17.3m
OBI Ondine Biomedical
23.9x66.0%UK£22.2m
CREO Creo Medical Group
2.1x-4.9%UK£64.3m
EMVC EMV Capital
5.8x49.2%UK£10.6m
AGL ANGLE
15.9x51.5%UK£32.3m

Price-To-Sales vs Peers: AGL is expensive based on its Price-To-Sales Ratio (15.9x) compared to the peer average (11x).

Price to Sales Ratio vs Industry

How does AGL's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
SPEC INSPECS Group
0.3x5.5%US$65.04m
YGEN Yourgene Health
0.6xn/aUS$20.48m
IHC Inspiration Healthcare Group
0.4x13.6%US$17.43m
SUN Surgical Innovations Group
0.4xn/aUS$6.44m
No more companies available in this PS range
AGL 15.9xIndustry Avg. 2.9xNo. of Companies4PS02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AGL is expensive based on its Price-To-Sales Ratio (15.9x) compared to the UK Medical Equipment industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is AGL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15.9x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: AGL is expensive based on its Price-To-Sales Ratio (15.9x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AGL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.10
UK£0.69
+585.0%
2.2%UK£0.70UK£0.67n/a2
Nov ’25UK£0.077
UK£0.69
+783.9%
2.2%UK£0.70UK£0.67n/a2
Oct ’25UK£0.083
UK£0.69
+730.3%
2.2%UK£0.70UK£0.67n/a2
Sep ’25UK£0.13
UK£0.69
+417.0%
2.2%UK£0.70UK£0.67n/a2
Aug ’25UK£0.14
UK£0.69
+380.7%
2.2%UK£0.70UK£0.67n/a2
Jul ’25UK£0.14
UK£0.69
+372.4%
2.2%UK£0.70UK£0.67n/a2
Jun ’25UK£0.19
UK£0.69
+265.3%
2.2%UK£0.70UK£0.67n/a2
May ’25UK£0.14
UK£0.69
+389.3%
2.2%UK£0.70UK£0.67n/a2
Apr ’25UK£0.13
UK£0.69
+448.0%
2.2%UK£0.70UK£0.67n/a2
Mar ’25UK£0.16
UK£0.69
+328.1%
2.2%UK£0.70UK£0.67n/a2
Feb ’25UK£0.17
UK£0.69
+302.9%
2.2%UK£0.70UK£0.67n/a2
Jan ’25UK£0.12
UK£0.97
+728.4%
18.9%UK£1.20UK£0.75n/a3
Dec ’24UK£0.12
UK£0.97
+704.4%
18.9%UK£1.20UK£0.75n/a3
Nov ’24UK£0.12
UK£0.97
+728.4%
18.9%UK£1.20UK£0.75UK£0.0773
Oct ’24UK£0.15
UK£0.97
+538.2%
18.9%UK£1.20UK£0.75UK£0.0833
Sep ’24UK£0.12
UK£0.94
+700.0%
24.0%UK£1.20UK£0.65UK£0.133
Aug ’24UK£0.14
UK£0.94
+548.3%
24.0%UK£1.20UK£0.65UK£0.143
Jul ’24UK£0.13
UK£0.94
+637.3%
24.0%UK£1.20UK£0.65UK£0.143
Jun ’24UK£0.18
UK£0.94
+415.1%
24.0%UK£1.20UK£0.65UK£0.193
May ’24UK£0.23
UK£0.94
+313.2%
24.0%UK£1.20UK£0.65UK£0.143
Apr ’24UK£0.20
UK£1.45
+625.0%
17.2%UK£1.70UK£1.20UK£0.132
Mar ’24UK£0.25
UK£1.45
+485.9%
17.2%UK£1.70UK£1.20UK£0.162
Feb ’24UK£0.29
UK£1.45
+400.0%
17.2%UK£1.70UK£1.20UK£0.172
Jan ’24UK£0.51
UK£2.06
+306.9%
17.3%UK£2.41UK£1.70UK£0.122
Dec ’23UK£0.54
UK£2.06
+284.1%
17.3%UK£2.41UK£1.70UK£0.122
Nov ’23UK£0.60
UK£2.06
+242.5%
17.3%UK£2.41UK£1.70UK£0.122

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Elevance Health

US$94.5b

Operates as a health benefits company in the United States.

0HG8

US$401.36

7D

1.7%

1Y

-16.0%

Centene

US$31.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.77

7D

3.9%

1Y

-17.3%

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

0KGB

US$21.06

7D

-0.8%

1Y

-32.9%